These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26060332)

  • 1. Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach.
    Janvilisri T; Leelawat K; Roytrakul S; Paemanee A; Tohtong R
    Dis Markers; 2015; 2015():105358. PubMed ID: 26060332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T
    J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.
    Sriwanitchrak P; Viyanant V; Chaijaroenkul W; Srivatanakul P; Gram HR; Eursiddhichai V; Na-Bangchang K
    Asian Pac J Cancer Prev; 2011; 12(6):1503-10. PubMed ID: 22126489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current omics-based biomarkers for cholangiocarcinoma.
    Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
    Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma.
    Rucksaken R; Charoensuk L; Pinlaor P; Pairojkul C; Khuntikeo N; Pinlaor S
    Cancer Biomark; 2017; 18(1):27-34. PubMed ID: 27814272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach.
    Pattanapairoj S; Silsirivanit A; Muisuk K; Seubwai W; Cha'on U; Vaeteewoottacharn K; Sawanyawisuth K; Chetchotsak D; Wongkham S
    Clin Biochem; 2015 Jul; 48(10-11):668-73. PubMed ID: 25863112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
    Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ
    Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.
    Betesh L; Comunale MA; Wang M; Liang H; Hafner J; Karabudak A; Giama NH; Moser CD; Miyoshi E; Roberts LR; Block TM; Mehta A
    Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28561948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
    Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma.
    Tolek A; Wongkham C; Proungvitaya S; Silsirivanit A; Roytrakul S; Khuntikeo N; Wongkham S
    Exp Biol Med (Maywood); 2012 Oct; 237(10):1142-9. PubMed ID: 23104505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum adhesion molecule-1 (ICAM-1) as a potential prognostic marker for cholangiocarcinoma patients.
    Janan M; Proungvitaya S; Limpaiboon T; Proungvitaya T; Roytrakul S; Wongkham C; Jearanaikoon P; Chur-in S; Wongkham S
    Asian Pac J Cancer Prev; 2012; 13 Suppl():107-14. PubMed ID: 23480771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
    Voigtländer T; Metzger J; Husi H; Kirstein MM; Pejchinovski M; Latosinska A; Frantzi M; Mullen W; Book T; Mischak H; Manns MP
    J Biomed Sci; 2020 Jan; 27(1):13. PubMed ID: 31900160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of bile and serum mucin5AC in cholangiocarcinoma: diagnostic performance and biologic significance.
    Danese E; Ruzzenente O; Ruzzenente A; Iacono C; Bertuzzo F; Gelati M; Conci S; Bendinelli S; Bonizzato G; Guglielmi A; Salvagno GL; Lippi G; Guidi GC
    Surgery; 2014 Nov; 156(5):1218-24. PubMed ID: 25151557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile.
    Wang B; Chen L; Chang HT
    Biomark Med; 2016 Jun; 10(6):613-9. PubMed ID: 27232281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Qualification of Serum Protein Biomarker Candidates for Cholangiocarcinoma Diagnosis.
    Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
    J Proteome Res; 2019 Sep; 18(9):3305-3316. PubMed ID: 31310545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of biliary alkaline phosphatase in non-jaundiced cholangiocarcinoma.
    Bhudhisawasdi V; Muisuk K; Areejitranusorn P; Kularbkaew C; Khampitak T; Saeseow OT; Wongkham S
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):87-92. PubMed ID: 14648209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Microfluidic Chip for Detecting Cholangiocarcinoma Cells in Human Bile.
    Hung LY; Chiang NJ; Tsai WC; Fu CY; Wang YC; Shan YS; Lee GB
    Sci Rep; 2017 Jun; 7(1):4248. PubMed ID: 28652576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.